Watsin Genetech

Watsin Genetech is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to the development of next-generation gene therapies. The company utilizes a proprietary Adeno-associated virus (AAV) vector platform to create treatments for ophthalmic, metabolic, and rare genetic disorders. Its lead program, WS011, is an AAV-delivered gene therapy designed to treat neovascular age-related macular degeneration by providing sustained expression of anti-VEGF proteins. Watsin Genetech's technology focuses on optimizing AAV capsids for improved tissue targeting and reduced immunogenicity. The firm was co-founded by Dr. Xiao Xiao, a globally recognized pioneer in the field of AAV research and gene therapy.